Rigel Pharmaceuticals announced Q2 2026 total revenues of $78.7 million, driven by $67.0 million in net product sales and $11.7 million from collaborations. The company expanded its commercial portfolio by in-licensing VEPPANU™, the first FDA-approved PROTAC for certain advanced breast cancers, expected to launch in the U.S. mid-August 2026. Rigel is progressing its R289 Phase 1b trial for lower-risk myelodysplastic syndrome, aiming to complete enrollment and select a Phase 2 dose in late 2026. The company raised its 2026 revenue outlook to $285-$295 million and expects to remain profitable while funding development programs.
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, ...
